00

Tibet Aim Pharm IncSHE 002826 Stock Report

Last reporting period 30 Sep, 2023

Updated 13 Nov, 2024

Last price

Market cap $B

0.213

Micro

Exchange

XSHE - Shenzhen Stock Exchange

002826.SZ Stock Analysis

00

Neutral

Based on Eyestock quantitative analysis, 002826.SZ`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

71/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

3.8 %

Undervalued

Market cap $B

0.213

Dividend yield

1.48 %

Shares outstanding

190.21 B

Tibet Aim Pharm., Inc. engages in the research and development, production, and sale of chemical drugs, and Chinese medicines. The company is headquartered in Chengdu, Sichuan and currently employs 430 full-time employees. The company went IPO on 2016-12-09. The Company’s products include self-manufacturing medicine and third-party medicine. Self-manufacturing medicine includes miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, as well as domperidone tablets, among others. Its third-party medicine includes gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, as well as carbetocin injection. The firm distributes its products within domestic market and to overseas markets.

View Section: Eyestock Rating